Accord Biopharma

Timeline

1. May 15, 2026 FDA FDA Original approval: IMMGOLIS; IMMGOLIS INTRI (golimumab-sldi) — BLA761452, May 15, 2026. Applicant at approval: Accord BioPharma, Inc. Biosimilar. source ↗
2. May 7, 2026 FDA FDA Original approval: ENNUMO (pegfilgrastim-pccg) — BLA761147, May 7, 2026. Applicant at approval: Accord BioPharma Inc. Biosimilar. source ↗
3. Jan 15, 2026 FDA FDA Original approval: FILKRI (filgrastim-laha) — BLA761027, Jan 15, 2026. Applicant at approval: Accord BioPharma Inc. (ABI). Biosimilar. source ↗
4. Oct 29, 2025 FDA FDA Original approval: JUBEREQ; OSVYRTI (denosumab-desu) — BLA761424, Oct 29, 2025. Applicant at approval: Accord BioPharma Inc. Biosimilar. source ↗
5. Feb 10, 2025 Partnership Partnership / licensing announced Feb 10, 2025. Source: company's own press page. source ↗
6. Oct 10, 2024 FDA FDA Original approval: IMULDOSA (ustekinumab-srlf) — BLA761364, Oct 10, 2024. Applicant at approval: Accord BioPharma, Inc. Biosimilar. source ↗

Funding

Last 2 years.

• Feb 10, 2025 Partnership / licensing announced Feb 10, 2025. Source: company's own press page. source ↗

FDA records (last 2 years)

• May 15, 2026 FDA Original approval: IMMGOLIS; IMMGOLIS INTRI (golimumab-sldi) — BLA761452, May 15, 2026. Applicant at approval: Accord BioPharma, Inc. Biosimilar. source ↗
• May 7, 2026 FDA Original approval: ENNUMO (pegfilgrastim-pccg) — BLA761147, May 7, 2026. Applicant at approval: Accord BioPharma Inc. Biosimilar. source ↗
• Jan 15, 2026 FDA Original approval: FILKRI (filgrastim-laha) — BLA761027, Jan 15, 2026. Applicant at approval: Accord BioPharma Inc. (ABI). Biosimilar. source ↗
• Oct 29, 2025 FDA Original approval: JUBEREQ; OSVYRTI (denosumab-desu) — BLA761424, Oct 29, 2025. Applicant at approval: Accord BioPharma Inc. Biosimilar. source ↗
• Oct 10, 2024 FDA Original approval: IMULDOSA (ustekinumab-srlf) — BLA761364, Oct 10, 2024. Applicant at approval: Accord BioPharma, Inc. Biosimilar. source ↗